American Biogenetic Sciences, Inc. (ABS) is a global biopharmaceuticals and diagnostics company conducting research and development at its own research facilities and through its Global Scientific Network in the US, Europe, Israel, and Russia. ABS seeks to discover and commercialize products in the fields of cardiovasculer diseases and neurobiology. The company's enabling technology includes a potential Antigen-free mouse colony which allows for the generation of highly specific monoclonal antibodies that cannot be acquired from conventional systems. American Biogenetic Sciences engages in research and development related to cardiovascular and neurobiology products. The company conducts research in China, Israel, the US, and Europe at its own facilities and through collaborations with institutions such as the Russian Academy of Medical Sciences. American Biogenetic Sciences develops in vivo and in vitro diagnostic tests that use monoclonal antibodies generated through an antigen-free mouse colony. The company is also developing a blood test for detecting Alzheimer's disease and chemical compounds to stop the progression of strokes, Alzheimer's, Parkinson's disease, amyotrophic lateral sclerosis, and other conditions.
